Xeris Biopharma Holdings, Inc. XERS
10.35 USD 0.00 (+0.00%)
At closeNov 4, 2026, 9:22 AM EST
10.65 +0.30 +2.87%
Pre-market · Nov 4, 9:22 AM ET
Day range unavailable
5.25 52-week range 11.42
- YTD
- +31.85%
- 1 year
- +4.55%
- Market cap
- 1.89B
- Revenue (ttm)
- 335.41M
- Profit margin
- -5.12%
- EPS (ttm)
- -0.10
- Shares out
- 182.32M
- Forward P/E
- 52.63
- YTD return
- +31.85%
- 1-year return
- +4.55%
- Avg volume
- 2.38M
- Previous close
- 10.35
- 52-week range
- 5.25 – 11.42
- Beta
- 0.84
- Price target
- 12.86 (+24.2%)
- Earnings date
- Nov 5, 2026
1D 0.00 (0.00%)
Key statistics
- Enterprise value
- 2.02B
- PEG ratio
- 0.00
- Price / sales
- 5.63
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 28.70%
- Free cash flow
- 52.45M
- Total cash
- 121.75M
- Total debt
- 289.44M
- Return on equity
- 0.00%
- Short % of float
- 4.55%
- 50-day average
- 9.34
- 200-day average
- 7.51
Analyst view
Price target (mean) 12.86 +24.2% upside
Now 10.35
- Target (low)
- 8.00
- Target (mean)
- 12.86
- Target (high)
- 18.00
Ratings (0m) 7 6 buy · 1 hold · 0 sell
- Strong buy1
- Buy5
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate 0.02667.
Financials — quick view
XERS Revenue — quarterly 92.10M
XERS Net income — quarterly -31.10M
XERS EPS — quarterly -0.18
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | 0.03167 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | 0.01214 | -0.18 | -0.19 | -1,582.70% |
| May 7, 2026 | Mar 31, 2026 | -0.00274 | 0.01 | +0.01 | +464.96% |
| Mar 2, 2026 | Dec 31, 2025 | 0.03 | 0.06 | +0.03 | +100.00% |
| Nov 6, 2025 | Sep 30, 2025 | 0.01 | 0.0035 | -0.01 | -65.00% |
| Aug 7, 2025 | Jun 30, 2025 | -0.03 | -0.01 | +0.02 | +66.67% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 6, 2026 | Barclays | main | Overweight | Overweight |
| Sep 10, 2026 | Leerink Partners | main | Outperform | Outperform |
| Aug 20, 2026 | Barclays | main | Overweight | Overweight |
| Mar 2, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Jan 9, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 9, 2025 | Barclays | init | — | Overweight |
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- xerispharma.com
News
Xeris Biopharma (NASDAQ:XERS) vs. Cocrystal Pharma (NASDAQ:COCP) Head-To-Head Contrast 
Xeris Biopharma Welcomes Menassie M. Taddese to Board of Directors 
Xeris Biopharma Holdings Inc (XERS) Stock Down 6.1% but Still Overvalued -- GF Score: 66/100 
Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026 
Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026 
Organon & Co. (NYSE:OGN) & Xeris Biopharma (NASDAQ:XERS) Critical Comparison 
Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings 
Xeris Biopharma Files Patent Infringement Lawsuits Related To Its KEYEVIS Product In U.S. District Court In New Jersey 
Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma 
Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $14
Your note
Sign in to keep a note on XERS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BORMANN-KENNEDY BARBARA-JEAN ANNE | Director | Stock Award(Grant) | Jun 3, 2026 | 150,693 |
| HECHT BETH P | Officer | Sale | Aug 31, 2026 | 1,127,800 |
| JOHNSON JOHN H. | Director | Sale | Dec 18, 2025 | 698,083 |
| KONG GARHENG | Director | Stock Award(Grant) | Jun 3, 2026 | 238,337 |
| MCCULLOCH KEVIN | President | Sale | Sep 27, 2026 | 1,639,210 |
| NGUYEN ANH TU | Officer | Stock Award(Grant) | Jan 29, 2026 | 431,534 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.97% | 14,525,539 | 150.34M | Jun 29, 2026 |
| Shaw D.E. & Co., Inc. | 4.28% | 7,804,758 | 80.78M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.03% | 7,340,229 | 75.97M | Jun 29, 2026 |
| State Street Corporation | 2.64% | 4,821,566 | 49.90M | Jun 29, 2026 |
| Geode Capital Management, LLC | 2.59% | 4,718,183 | 48.83M | Jun 29, 2026 |
| Nuveen, LLC | 2.41% | 4,385,141 | 45.39M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.85% | 5,193,656 | 53.75M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.42% | 4,417,108 | 45.72M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.09% | 1,986,461 | 20.56M | Jun 29, 2026 |
| College Retirement Equities Fd.-College Retirement Equities Fd. - Tota | 1.07% | 1,951,890 | 20.20M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.03% | 1,872,201 | 19.38M | Aug 30, 2026 |
| iShares Trust-iShares Russell 2000 Growth ETF | 0.88% | 1,595,993 | 16.52M | Sep 29, 2026 |